Bioorganic
264 papers17 directions
Bioorganic is a research venue that has been active since 1991, with a collection of 263 papers documented through 2026. The venue focuses on the intersection of chemical biology and drug discovery, providing a platform for research into the design, synthesis, and biological evaluation of small molecules. Its scope encompasses a variety of therapeutic areas, including oncology, immunology, and antifungal treatments. Prolific contributors to the venue include researchers such as Thierry Langer, Andreas Verras, and Dong‐Ming Shen.
The research published at Bioorganic frequently centers on the identification of potent inhibitors and the development of novel molecular scaffolds. Sample studies include the discovery of mTOR inhibitors for acute myeloid leukemia, URAT1 inhibitors with hypouricemic effects, and the design of PD-L1-targeted molecules for cancer therapy. The venue also features work on molecular glue degraders and natural product-inspired derivatives, reflecting a focus on diverse chemical strategies for modulating biological targets.
In the context of machine learning and computational research, Bioorganic serves as a site for the application of molecular design technologies and structural analysis. The venue documents the use of emerging insights in immunomodulatory technologies and the identification of selective inhibitors, such as those targeting ROCK2 or tubulin polymerization. By publishing detailed findings on structure-activity relationships and oral bioavailability, the venue contributes to the data and methodologies used in the computational screening and optimization of therapeutic candidates.
Papers by Year
Top Research Directions
Research directions most represented by papers from this venue.
Top Authors
Impactful Papers
Papers from this venue that shaped research clusters.
Foundational
Influential
Related Venues
Venues with the most similar research cluster distributions.
Papers
| Title | Year |
|---|
| Design and an efficient synthesis of natural product-based cyclopenta[b]pyran derivatives with potential bioactivity | 2010 |
| Design and an efficient synthesis of new thiorotenone derivatives | 2010 |
| Design and efficient synthesis of A-278637 derivatives as potential potassium channel opener | 2010 |
| Discovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion inhibitors | 2010 |
| First identification of xanthone sulfonamides as potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors | 2010 |
| Highly brominated metabolites from marine red alga Laurencia similis inhibit protein tyrosine phosphatase 1B | 2010 |
| Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays | 2010 |
| Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening | 2010 |
| Morphinans and isoquinolines: Acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors | 2010 |
| On the inhibition of histone deacetylase 8 | 2010 |
| Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives | 2010 |
| Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors | 2010 |
| 20(R)-Ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity | 2009 |
| 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors | 2009 |
| Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A2A and A3 receptor pyrazolo-t | 2009 |
| Designed DNA probes from the neocarzinostatin family: Impact of glycosyl linkage stereochemistry on bulge base binding | 2009 |
| Detection of multiple network-based allosteric interactions between peptides and arrays of DNA binding sites | 2009 |
| Low molecular weight non-peptide mimics of ω-conotoxin GVIA | 2009 |
| Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds | 2009 |
| Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors | 2009 |
| Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors | 2009 |
| ω-Conotoxin GVIA mimetics based on an anthranilamide core: Effect of variation in ammonium side chain lengths and incorporation of fluorine | 2009 |
| Discovery of GSK345931A: An EP1 receptor antagonist with efficacy in preclinical models of inflammatory pain | 2008 |
| Efficient parallel synthesis of macrocyclic peptidomimetics | 2008 |
| Heme activates artemisinin more efficiently than hemin, inorganic iron, or hemoglobin | 2008 |
| Inhibition of Candida albicans isocitrate lyase activity by sesterterpene sulfates from the tropical sponge Dysidea sp. | 2008 |
| IRAK-4 inhibitors. Part 1: A series of amides | 2008 |
| IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding | 2008 |
| IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines | 2008 |
| Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives | 2008 |
| 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases | 2007 |
| A polyacetylene compound from herbal medicine regulates genes associated with thrombosis in endothelial cells | 2007 |
| Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones | 2007 |
| Synthesis of novel neutrophil-specific imaging agents for Positron Emission Tomography (PET) imaging | 2007 |
| Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety | 2006 |
| Design, synthesis, and SAR analysis of novel selective σ1 ligands | 2006 |
| Factor VIIa inhibitors: Gaining selectivity within the trypsin family | 2006 |
| Molecular probes of DNA bulges: Functional assay and spectroscopic analysis | 2006 |
| Active site binding modes of curcumin in HIV-1 protease and integrase | 2005 |
| Constructing plasma protein binding model based on a combination of cluster analysis and 4D-fingerprint molecular similarity analyses | 2005 |
| Development of α-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease | 2005 |
| New leads of metallo-β-lactamase inhibitors from structure-based pharmacophore design | 2005 |
| Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors | 2005 |
| Synthesis and evaluation of diverse analogs of amygdalin as potential peptidomimetics of peptide T | 2005 |
| Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa | 2004 |
| Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase | 2004 |
| QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids | 2004 |
| Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor | 2004 |
| A biaryl peptide crosslink in a MetJ peptide model confers cooperative, nonspecific binding to DNA that ablates both repressor binding and In vitro transcription | 2003 |
| Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of at | 2003 |
« prev Page 5/6 next »